Eli Lilly Trounces Nvidia as the Weight-Loss Trade Beats AI Again
Since Nvidia's Oct. 6 record, the chipmaker has lost more than $1.7 trillion in market value while Eli Lilly, maker of Zepbound and Mounjaro, has added more than $250 billion. Lilly is up 25% against Nvidia's 32% drop, and the weight-loss trade that lagged Big Tech for two years is back in the lead.
The weight-loss drug trade is beating AI again. Since Nvidia (NVDA) hit its record on Oct. 6, the chipmaker has lost more than $1.7 trillion in market value, while Eli Lilly (LLY), the maker of Zepbound and Mounjaro, has added more than $250 billion. Through Friday's close, that was a 25% gain for Lilly against a 32% drop for Nvidia, and the gap widened again Monday, a day before Nvidia's first earnings report since Jensen Huang's exit.
Winners and losers since Oct. 6
| Stock | Market value change, Oct. 6 to Nov. 13 |
|---|---|
| Apple (AAPL) | ▲ About $329 billion |
| Eli Lilly (LLY) | ▲ About $269 billion |
| Walmart (WMT) | ▲ About $166 billion |
| Micron (MU) | ▼ About $300 billion |
| SpaceX (SPCX) | ▼ About $450 billion |
| Alphabet (GOOGL) | ▼ About $640 billion |
| Nvidia (NVDA) | ▼ More than $1.7 trillion |
Among the market's biggest stocks, only Apple has added more value than Lilly since Nvidia peaked. It is the same lineup that emerged in October, when AI stocks lost about $5 trillion in less than a month and Lilly led the winners.
Why Lilly is winning
- Blowout growth. Lilly's third-quarter revenue rose 39% to $24.4 billion, and it lifted its 2026 sales forecast to $91 billion to $92 billion.
- New markets. China approved Lilly's oral weight-loss pill orforglipron last week, opening one of the world's largest obesity markets to a pill rather than an injection.
- Wall Street support. Morgan Stanley raised its price target to $1,596. Lilly closed Friday at $1,443.50, giving it a market value of about $1.29 trillion.
- A safe-haven bid. As money flees AI and chip stocks, investors have favored companies with steady, visible earnings, a group that also includes Apple and Walmart.
The GLP-1 trade, round two
Weight-loss drugmakers were Wall Street's other obsession early in this bull market. In the 15 months after the October 2022 low, Lilly and Novo Nordisk (NVO) gained about 92% on average, close to the Magnificent Seven's 101%. Then the trade broke down: Novo lost about three-quarters of its value from its June 2024 peak, and the group spent two years watching Big Tech lead. Now the roles have flipped, and Lilly has pulled ahead of Nvidia over the past five years.
What to watch
- Nvidia earnings. A strong report after Tuesday's close could pull money back toward AI and slow the rotation.
- Orforglipron launch. How quickly Lilly's weight-loss pill ramps in the U.S. and China.
- Pricing. Whether lower realized prices for Zepbound and Mounjaro keep being offset by higher volumes.
- Valuation. Lilly's premium multiple leaves little room for a stumble.
This article is informational only and is not investment advice.
Readers also read
Buffett Favorites Apple, Coca-Cola and Berkshire Hit Records as Nvidia Sinks
Earnings PreviewNvidia Faces First Earnings Without Jensen Huang as Kress Takes the Call
MarketsStocks Slide Ahead of AI's Big Week: Nvidia Earnings and Anthropic's $1.4 Trillion IPO
SpaceSpaceX Catches Starship for the First Time; Analysts Say Rockets Drive Its Value
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.
